Main Menu
Menu

Council for Innovation Promotion

Publish Date
BlogFact Checks
Fact Check: The Data Doesn’t Support the Existence of So-Called Patent “Thickets”

Several academic authors recently published an article in Health Affairs Forefront advising policymakers in Congress and at the USPTO on the best...

Resources
Infographics & Fact Sheets
PREVAIL in Comparison to the Current and Previous Administration’s Procedures for PTAB
News
Fake gifts flooding online marketplaces this holiday season. Here’s how to avoid getting scammed.
KTNV-TV
Blog
‘Tis the Season — of Counterfeits?

Counterfeiting is a multi-billion-dollar enterprise that puts consumers at serious risk. Poorly-made laptop batteries can overheat. Knock-off cosmetics may contain toxic chemicals....

News
The Patent Eligibility Restoration Act (PERA) Could Provide A Much Needed Boost To Key Technology Sectors Of The U.S. Economy
Mondaq
Press Releases
Council for Innovation Promotion Statement on RALIA and the BIA

WASHINGTON (November 10, 2025) — Recently, Representatives Thomas Massie (R-KY), Marcy Kaptur (D-OH), Michael Cloud (R-TX), Warren Davidson (R-OH), Paul Gosar (R-AZ),...

Blog
This Month in IP: October 2025

Strong, consistent IP protections throughout U.S. history enabled the creation of innovative and useful technologies that we use regularly today. From firefighting...

Blog
C4IP Coalition Updates: October 2025

October Highlights: C4IP Advocates for the Patent Eligibility Restoration Act On October 8, the Senate Judiciary Subcommittee on Intellectual Property held a...

News
C4IP Urges USTR to Use USMCA Joint Review to Address Shortcomings on IP Protections
IPWatchdog
Resources
Public Comments
C4IP Comments RE: India’s Invitation to Comment on Its Drug Approval Regime
Resources
Public Comments
C4IP Comments RE: Operation of the Agreement between the United States of America, the United Mexican States, and Canada (USTR-2025-0004)
Blog
Why Continued Innovation Matters: Keytruda and the “Product Hopping” Myth

The FDA recently approved a new version of Keytruda, a cancer immunotherapy medicine that is one of the world’s most successful drugs....

Op-Eds:

Op-Eds:

Big Tech is abusing the U.S. patent challenge system,

02/18/2022
Op-Eds:

Op-Eds:

Thank You, Senator Tillis, for Recognizing the Need for Evidence-Based Policymaking in Patent Law,

02/15/2022
Op-Eds:

Op-Eds:

The Supreme Court is partly to blame for the Covid-19 test kit shortage,

02/07/2022
Op-Eds:

Op-Eds:

Can We Please Get Serious About Patents and Drug Pricing?,

01/06/2022
Op-Eds:

Op-Eds:

World leaders should acknowledge that IP protections facilitate vaccine access,

12/24/2021
Resources:

Resources:

USIJ White Paper on Fintiv Doctrine,

11/29/2021
Op-Eds:

Op-Eds:

Why does the FDA want to stop improving medicines via patent ‘areas of concern’?,

11/08/2021
Op-Eds:

Op-Eds:

Time to Fight Back Against Big Tech’s IP Assault,

10/25/2021
Op-Eds:

Op-Eds:

Biden is trying to undermine America’s world-leading IP protections,

08/11/2021
Op-Eds:

Op-Eds:

Federal Tech, Trade Bill Needs IP Owner Transparency Tweaks,

06/30/2021
Op-Eds:

Op-Eds:

Waiving Covid-19 vaccine patents won’t get shots in arms faster. It slows down new vaccines.,

05/25/2021
Op-Eds:

Op-Eds:

No evidence that patents slow access to vaccines,

04/13/2021
Scroll to Top